Fujirebio Acquires ADx NeuroSciences

argenx to Acquire Forte Biosciences, Inc.

July 27, 2026

Healthcare Services

argenx entered into a definitive agreement to acquire Forte Biosciences, Inc. for $77 per share in cash, valuing the deal at approximately $2.2 billion. The transaction will be implemented via a tender offer followed by a merger, and is expected to close in Q3 2026 subject to customary closing conditions.

Eurobio Scientific Acquires CareDx Lab Products Division

April 16, 2026

Healthcare Services

Eurobio Scientific entered into a definitive agreement to acquire CareDx’s Lab Products transplant lab products division for €145 million (about $170 million) in cash. The deal will integrate the acquired Lab Products portfolio into Eurobio’s GenDx operations and is intended to expand GenDx’s comprehensive transplantation IVD workflow, from pre-transplant HLA typing to post-transplant monitoring solutions.

Nihon Kohden Acquires 71.4% Stake in Ad‑Tech from ARCHIMED

November 26, 2024

Medical Devices

Nihon Kohden has acquired a 71.4% stake in NeuroAdvanced Corp., the parent of Ad‑Tech Medical Instrument Corporation, from ARCHIMED’s MED II fund, with ARCHIMED retaining a 28.6% minority stake and entering a joint venture with Nihon Kohden. The deal brings together Nihon Kohden’s EEG and monitoring platform with Ad‑Tech’s intracranial neuroelectrodes to strengthen epilepsy diagnostics and expand Ad‑Tech’s global reach across North America, Europe and Asia.

Novartis Acquires DTx Pharma

July 17, 2023

Biotechnology

Novartis has acquired DTx Pharma, a San Diego–based preclinical biotechnology company, for an upfront payment of USD 500 million plus contingent milestone payments. The deal brings DTx's FALCON siRNA delivery platform and lead program DTx-1252 (orphan-designated for CMT1A) into Novartis to strengthen its neuroscience pipeline and xRNA capabilities.

Eurobio Scientific Acquires GenDx (Genome Diagnostics B.V.)

October 4, 2022

Biotechnology

Paris-based Eurobio Scientific has acquired all outstanding shares of Dutch transplant diagnostics specialist GenDx (Genome Diagnostics B.V.), following a share purchase agreement signed on August 17. The acquisition expands Eurobio's molecular diagnostics portfolio in transplantation and secures the company legacy with proceeds funding a GenDx foundation established by the founders.

BioVie Acquires Biopharma Assets of NeurMedix

June 11, 2021

Pharmaceuticals

BioVie Inc. acquired the biopharmaceutical assets of privately held NeurMedix, including NE3107, an orally administered small-molecule inhibitor targeting neuroinflammation and insulin resistance. The deal paid NeurMedix shareholders newly issued BioVie shares and cash at closing, with additional contingent cash and equity payments tied to clinical and regulatory milestones; the acquisition expands BioVie's pipeline into neurodegenerative diseases and oncology.